{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:27:44Z","timestamp":1786728464305,"version":"build-2736575974"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"\n Background:<\/jats:title>\n Minor adverse event following immunizations (AEFIs) are often underreported and self-treated. This study aimed to collect information regarding any and every probable adverse event experienced by the recipient of Covishield vaccine up to 10 days following the first and second dose of vaccine. To find the incidence of minor adverse events following Covishield vaccination; draw an association between adverse events and individuals' demographic factors and comorbidities; and report new adverse events, if any.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n A descriptive observational study was conducted among 409 participants randomly sampled from the Vaccination Centre at a Tertiary Care Hospital, Mumbai. Participants were followed up post their first and second doses to enquire about adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Most commonly reported adverse events included injection site pain, tenderness, chills, fatigue, fever, and myalgia. Females reported more adverse events compared to men (\n p<\/jats:italic>\n < 0.05). Younger individuals (18\u201324) experienced adverse events more as compared to individuals above 40 years of age (\n p<\/jats:italic>\n < 0.005). Reported adverse events were lesser after the second dose in comparison with the first dose. Few participants reported dysgeusia.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Covishield vaccination has a mild AEFI profile, most commonly: injection site pain, tenderness, chills, and fatigue. It is hoped that the findings of this study will dispel anxiety around the adverse events of vaccination and reduce any persisting vaccine hesitancy. Effective communication with the population on vaccination will enable individuals to make educated and informed decisions.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijcm.ijcm_93_22","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T01:28:23Z","timestamp":1709774903000},"page":"613-617","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study"],"prefix":"10.4103","volume":"47","author":[{"given":"Gajanan D.","family":"Velhal","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash V.","family":"Kamath","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansh S.","family":"Agrawal","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devanshi S.","family":"Vora","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav R.","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,16]]},"reference":[{"key":"R6-20250718","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.3346\/jkms.2021.36.e107","article-title":"Adverse events in healthcare workers after the first dose of chadox1 ncov-19 or bnt162b2 mrna covid-19 vaccination: a single center experience","volume":"36","author":"Kim","year":"2021","journal-title":"J Korean Med Sci"},{"key":"R7-20250718","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.3346\/jkms.2021.36.e115","article-title":"Adverse reactions following the first dose of chadox1 ncov-19 vaccine and bnt162b2 vaccine for healthcare workers in South Korea","volume":"36","author":"Bae","year":"2021","journal-title":"J Korean Med Sci"},{"key":"R8-20250718","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/jcm10132844","article-title":"Systemic adverse events and use of antipyretics predict the neutralizing antibody positivity early after the first dose of chadox1 coronavirus disease vaccine","volume":"10","author":"Park","year":"2021","journal-title":"J Clin Med"},{"key":"R10-20250718","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.1016\/j.mjafi.2021.06.014","article-title":"Adverse events following ChAdOx1 nCoV-19 Vaccine (Covishield) amongst health care workers: A prospective observational study","volume":"77","author":"Kamal","year":"2021","journal-title":"Med J Armed Forces India"},{"key":"R11-20250718","doi-asserted-by":"crossref","first-page":"162","DOI":"10.4103\/cmi.cmi_50_21","article-title":"How safe is Covishield (ChAdOx1nCoV-19) Vaccine? Experience from a Tertiary Care Hospital in South India [Internet]","volume":"19","author":"Inbaraj","year":"2021","journal-title":"Current Medical Issues"},{"key":"R12-20250718","doi-asserted-by":"crossref","first-page":"284","DOI":"10.5455\/njcm.20210801045238","article-title":"A longitudinal study on adverse events following covid-19 vaccination among healthcare workers in a tertiary care hospital in Tiruvallur district, Tamil Nadu","volume":"12","author":"Jain","year":"2021","journal-title":"Natl J Community Med"},{"key":"R13-20250718","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1473-3099(21)00224-3","article-title":"Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study","volume":"21","author":"Menni","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R15-20250718","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","article-title":"Phase 3 safety and efficacy of azd1222 (ChAdOx1 nCoV-19) covid-19 vaccine","volume":"385","author":"Falsey","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Indian Journal of Community Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_93_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:21Z","timestamp":1786724841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijcm.ijcm_93_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijcm.ijcm_93_22","relation":{},"ISSN":["0970-0218","1998-3581"],"issn-type":[{"value":"0970-0218","type":"print"},{"value":"1998-3581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"2022-01-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}